title: Maternal drug treatment and human milk banking.
abstract: We studied prospectively during one year temporary drug use by mothers donating breast milk to assess the problem of drug treatment of donors. Sixty-four of the 284 mothers (22.5%) had to abstain from donating due to medication. The indication was infection in 50/56 treatments (89.3%). Antimicrobial agents were prescribed 44/52 times (84.6%). The channelling of milk from mothers in early phases of lactation to premature and newborn infants was identified as a special risk situation, if mothers on medication are not excluded. The limited number of such donors leads to use of milk unpooled or pooled to small volumes with increased risk for adverse effects to babies as a consequence. We recommend a wash-out period of 5 half-lives of the drug after the last ingested dose. For the majority of drugs in this study, with some important exceptions, a wash-out period of 1 day was sufficient.
authors: Children's Hospital, 2nd Department of Pediatrics, University of Helsinki, Finland.
authors: K
authors: K
authors: Hoppu
authors: K
authors: K
authors: Kettunen
authors: R
authors: R
authors: Remes
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism; D000996:Antitussive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism; D001726:Bisacodyl / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism; D004350:Drug Residues / Q000009:adverse effects / Q000378:metabolism; D004394:Dydrogesterone / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism; D005260:Female; D006207:Half-Life; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D017784:Milk Banks / Q000592:standards*; D008895:Milk, Human / Q000737:chemistry / Q000378:metabolism*; D011446:Prospective Studies; D016593:Terfenadine / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism
chemical_list: D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000996:Antitussive Agents; D001726:Bisacodyl; D016593:Terfenadine; D004394:Dydrogesterone